Tumor deposits should not be placed in the M category of TNM: A comparative survival analysis using SEER data
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Tumor deposits (TD) in colorectal cancer patients negatively impact survival. This study found TD do not warrant reclassification to Stage IV, despite their poor prognosis, as Stage III patients with TD fare better than Stage IV patients.
Area Of Science
- Oncology
- Cancer Research
- Clinical Pathology
Background
- Tumor deposits (TD) are nodules in the lymphatic drainage of colorectal cancer (CRC) patients.
- Currently classified under the N category in TNM staging, TD are associated with poor prognosis.
- Previous small studies suggested reclassifying TD to the M category.
Purpose Of The Study
- To evaluate the prognostic impact of tumor deposits (TD) in Stages III and IV colon carcinoma (CC).
- To assess whether TD should be reclassified to the M category based on survival outcomes.
- To analyze survival differences between Stage III and Stage IV CC patients with and without TD.
Main Methods
- Retrospective analysis of The Surveillance, Epidemiology, and End Results (SEER) program data.
- Inclusion of 52,332 patients diagnosed with Stage III and IV colon carcinoma (CC).
- Multivariate analysis to determine the independent prognostic effect of TD on survival.
Main Results
- TD significantly and negatively affect survival in both Stage III (HR=1.4) and Stage IV (HR=1.3) CC.
- Five-year overall survival (OS) for Stage III CC patients with TD was 49% vs. 64% without TD (p<.001).
- Five-year OS for Stage IV CC patients with TD was 10% vs. 21% without TD (p<.001).
- Stage III CC patients with TD (5-year OS 49%) had a significantly better prognosis than Stage IV patients (5-year OS 17%, p<.001).
Conclusions
- Tumor deposits (TD) are a significant negative prognostic factor in both Stage III and IV colon carcinoma.
- Despite their poor prognosis, the data do not support reclassifying TD to Stage IV.
- Stage III colon carcinoma patients with TD demonstrate a better survival outcome compared to Stage IV patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...